Skip to main content
. 2017 Sep 12;114(39):10455–10460. doi: 10.1073/pnas.1710754114

Fig. S4.

Fig. S4.

Blockade of CXCR4 enhances survival of animals bearing CRCs compared with anti-VEGFR2 therapy alone. (A) Mice bearing SL4 tumors were treated with control (C, black traces), AMD3100 (A, blue traces), DC101 (D, red traces), or dual therapy (A+D, green traces). DC101 monotherapy led to significantly higher overall median survival (18 d) than control treatment (14.5 d). Dual therapy led to a significantly higher median survival (20.5 d) than control or DC101 treatment. n = 10 per group. *P < 0.05. (B) Mice bearing CT26 tumors were treated with control (C, black traces), AMD3100 (A, blue traces), DC101 (D, red traces), or dual therapy (A+D, green traces). DC101 monotherapy led to significantly higher overall median survival (19.5 d) than AMD3100 treatment (17 d) but not higher than control treatment (19 d). Dual therapy led to a significantly higher median survival (33 d) than control or DC101 treatment. n = 9–10 per group. *P < 0.05.